L26/P-783 150 IU versus 225 IU starting dose of recombinant FSH in predicted normal ovarian responders: A Randomized Controlled Trial
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.1110 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von D. Zhang und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Study question Does a higher initial recombinant FSH dose (225 IU) yield more oocytes than standard 150 IU in predicted normal responders? Summary answer A 225 IU FSH starting dose in normoresponders yields similar oocyte numbers and live birth rates but lower blastulation than 150 IU. What is known already Current guidelines recommend a broad initial recombinant FSH dose range of 150–225 IU for predicted normal ovarian responders; however, robust evidence to support one starting dose over another remains lacking. Defining the optimal FSH starting dose is crucial to maximize clinical efficacy while minimizing treatment burden and asscoiated risks. Study design, size, duration This open-label, single-center, randomized controlled trial enrolled participants between November 2021 and March 2024, with follow-up completed by December 2025. On menstrual cycle day 2, women were randomized 1:1 to initiate ovarian stimulation with either 150 IU or 225 IU of recombinant FSH within a flexible GnRH antagonist protocol. Follow-up continued until the first live birth or no viable embryos remained. Participants/materials, setting, methods We included women aged ≤38 years undergoing their first IVF/ICSI cycle, with an antral follicle count of 7-15, AMH >1.11 ng/mL, and body mass index between 18 and 25 kg/m². The primary outcome was the number of cumulus–oocyte complexes (COCs) retrieved. Secondary outcomes included embryological parameters, reproductive outcomes per transfer, and cumulative live birth rate. Analyses were conducted on an intention-to-treat basis. Main results and the role of chance Of the 182 randomized women, 93 were assigned to the 225 IU group and 89 to the 150 IU group. The median number of cumulus–oocyte complexes (COCs) retrieved was similar between groups: 11 (IQR 7–15) vs. 10 (IQR 7–16); P = 0.87. The blastulation rate was significantly lower in the 225 IU group (65.2% vs. 72.1%; risk difference −6.9%, 95% CI: −12.7 to − 1.1; P = 0.02). Cumulative live birth rates were comparable (62.4% vs. 66.3%; risk difference −3.9%, 95% CI: −17.8 to 10; P = 0.69). Limitations, reasons for caution Limitations include single-center design, modest sample size, and protocol flexibility allowing rFSH dose adjustments (±75 IU increments), which may have diluted treatment effects. Generalizability is limited to strict normal responders. Wider implications of the findings These findings support 150 IU as the optimal starting dose of recombinant FSH for predicted normal ovarian responders, yielding comparable oocyte retrieval and cumulative live birth rates. This supports a more conservative and patient-friendly ovarian stimulation strategy in routine IVF practice for normal responders. Trial registration number Yes
Zitieren
APA
Zhang, D., He, C., & Juanzi, S. (2026). L26/P-783 150 IU versus 225 IU starting dose of recombinant FSH in predicted normal ovarian responders: A Randomized Controlled Trial. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.1110
Vancouver
Zhang D, He C, Juanzi S. L26/P-783 150 IU versus 225 IU starting dose of recombinant FSH in predicted normal ovarian responders: A Randomized Controlled Trial. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.1110
BibTeX
@article{Zhang2026,
author = {Zhang, D. and He, C. and Juanzi, S.},
title = {L26/P-783 150 IU versus 225 IU starting dose of recombinant FSH in predicted normal ovarian responders: A Randomized Controlled Trial},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.1110}
}
EUVIMED